Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
NACRES:
NA.54
UNSPSC Code:
12352204
Product Name
Microsomes from Liver, Pooled, from human male
biological source
human male
form
liquid
packaging
vial of ~10 mg
shipped in
dry ice
storage temp.
−70°C
Quality Level
Looking for similar products? Visit Product Comparison Guide
Application
Microsomes from Liver, Pooled has been used:
- in the glucuronidation kinetics assay to test the effects of herbal extracts on glucuronidation process
- as a human liver microsomes (HLM) matrix for testing metabolic stability of talazoparib using liquid chromatography-tandem mass spectrometry (LC–MS/MS)
- to study the metabolization of enantiomeric peptide D3
Microsomes from liver have been used in a study to assess differences in enzymatic activities between normal rat livers and from liver after partial hepatectomy. They have also been used in a study to investigate the carbon monoxide-binding pigment in liver microsomes.
Biochem/physiol Actions
Liver microsomes are subcellular particles derived from the endoplasmic reticulum of hepatic cells. These microsomes are a rich source of drug metabolizing enzymes, including cytochrome P-450. Microsome pools from various sources are useful in the study of xenobiotic metabolism and drug interactions.
N-glucuronidation of various 1-substituted imidazoles was found to occur in human liver microsomes.
Source of drug metabolizing enzymes, including cytochrome P-450.
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mohamed W Attwa et al.
Drug design, development and therapy, 14, 111-119 (2020-02-06)
Larotrectinib (VITRAKVI) is an orally potent tropomyosin receptor kinase (Trk) inhibitor that acts by competitive inhibition of all corresponding receptor kinases. It demonstrated a marked response rate (75%) and robust anticancer activity in Trk fusion-positive patients. This response is independent
Mohamed W Attwa et al.
Drug design, development and therapy, 14, 783-793 (2020-03-12)
Talazoparib (BMN673) is a new poly(ADP-ribose) polymerase inhibitor that has been FDA approved for patients suffering from metastatic breast cancer with germline BRCA mutations. In the current study, an accurate and efficient liquid chromatography-tandem mass spectrometry (LC-MS/MS) analytical methodology was
The Carbon Monoxide-binding pigment of liver microsomes II. Solubilization, purification and properties.
Omura, T. and Sato, R.
Journal of Biochemistry, 239, 2379-2385 (1964)
Mohamed W Attwa et al.
Drug design, development and therapy, 15, 3915-3925 (2021-09-24)
Rociletinib (CO-1686; RLC) is a new, small molecule that is orally administered to inhibit mutant-selective covalent inhibitor of most epidermal growth factor receptor (EGFR)-mutated forms, including T790M, L858R, and exon 19 deletions, but not exon 20 insertions. Non-small-cell lung cancer
The enzymatic composition of rat liver microsomes during liver regeneration.
von der DECKEN et al.
Experimental cell research, 19, 591-604 (1960-04-01)
Related Content
Datasheet
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service